Home NDC 68788-4009 Combogesic
Product NDC 68788-4009
11-digit product format 687884009
Labeler code 68788
Product ID 68788-4009_cd03b658-dba1-4a12-8f6f-ab00da499c05
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name ACETAMINOPHEN and IBUPROFEN
Dosage form TABLET, FILM COATED
Route ORAL
Labeler Preferred Pharmaceuticals Inc.
Application NDA209471
Marketing category NDA
Marketing start 2025-09-04
Substance ACETAMINOPHEN; IBUPROFEN
Active strength 325; 97.5 mg/1; mg/1
Pharmacologic classes Anti-Inflammatory Agents, Non-Steroidal [CS], Cyclooxygenase Inhibitors [MoA], Nonsteroidal Anti-inflammatory Drug [EPC]
NDC exclude flag No
Listing certified through 2026-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 1 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N209471-001 COMBOGESIC ACETAMINOPHEN; IBUPROFEN 325MG;97.5MG TABLET / ORAL RLD, RS 2023-03-01
Orange Book patents# Current patent rows page 1 of 1 · 2 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 N209471-001 11534407 2039-02-27 U-3553 Drug product 2023-03-29
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 1 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N209471-001 NP 2026-03-01
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-02-19 14:30 UTC 2026-02 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD, RS 2023-03-01 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD, RS 2023-03-01 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD, RS 2023-03-01 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD, RS 2023-03-01 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD, RS 2023-03-01 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD, RS 2023-03-01 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD, RS 2023-03-01 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD 2023-03-01 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD, RS 2023-03-01 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD, RS 2023-03-01 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD 2023-03-01 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD 2023-03-01 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD 2023-03-01 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD 2023-03-01 8072bd15b7f6…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD 2023-03-01 6a51e52b5d6a…2024-02-18 07:12 UTC 2024-02 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD 2023-03-01 1c564ffb4f44…2023-12-20 04:57 UTC 2023-12 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD 2023-03-01 ea1830bbd6c7…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD 2023-03-01 a72a2bbeb626…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD 2023-03-01 9b2671bbb829…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD, RS 2023-03-01 a67488948f0b…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD, RS 2023-03-01 3f0d92c62455…2023-05-13 08:27 UTC 2023-05 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD, RS 2023-03-01 053a50430f4f…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N209471-001 COMBOGESIC 325MG;97.5MG TABLET / ORAL RLD, RS 2023-03-01 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 2 · 67 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-02-19 14:30 UTC 2026-02 N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N209471-001 11534407 2039-02-27 U-3553 Drug product 2023-03-29 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209471-001 10532036 2025-09-22 U-3553 2023-03-29 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N209471-001 11534407 2039-02-27 U-3553 Drug product 2023-03-29 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N209471-001 10532036 2025-09-22 U-3553 2023-03-29 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N209471-001 11534407 2039-02-27 U-3553 Drug product 2023-03-29 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N209471-001 10532036 2025-09-22 U-3553 2023-03-29 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N209471-001 11534407 2039-02-27 U-3553 Drug product 2023-03-29 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N209471-001 10532036 2025-09-22 U-3553 2023-03-29 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N209471-001 11534407 2039-02-27 U-3553 Drug product 2023-03-29 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N209471-001 10532036 2025-09-22 U-3553 2023-03-29 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N209471-001 11534407 2039-02-27 U-3553 Drug product 2023-03-29 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N209471-001 10532036 2025-09-22 U-3553 2023-03-29 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 2680178bc6a6…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N209471-001 11534407 2039-02-27 U-3553 Drug product 2023-03-29 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N209471-001 10532036 2025-09-22 U-3553 2023-03-29 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 5bbf6a4d5a75…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N209471-001 11534407 2039-02-27 U-3553 Drug product 2023-03-29 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N209471-001 10532036 2025-09-22 U-3553 2023-03-29 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 d8e5a09893c0…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N209471-001 11534407 2039-02-27 U-3553 Drug product 2023-03-29 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N209471-001 10532036 2025-09-22 U-3553 2023-03-29 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 d06236e962d9…2024-10-29 15:01 UTC 2024-10 N209471-001 11534407 2039-02-27 U-3553 Drug product 2023-03-29 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N209471-001 10532036 2025-09-22 U-3553 2023-03-29 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 79d66fd596c7…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N209471-001 11534407 2039-02-27 U-3553 Drug product 2023-03-29 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N209471-001 10532036 2025-09-22 U-3553 2023-03-29 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 301d65b070ca…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N209471-001 11534407 2039-02-27 U-3553 Drug product 2023-03-29 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N209471-001 10532036 2025-09-22 U-3553 2023-03-29 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 1e350fbaab3a…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N209471-001 11534407 2039-02-27 U-3553 Drug product 2023-03-29 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N209471-001 10532036 2025-09-22 U-3553 2023-03-29 8072bd15b7f6…2024-05-31 18:47 UTC 2024-05 N209471-001 11197830 2039-02-27 U-3553 Drug product 2023-03-29 8072bd15b7f6…
Observed Orange Book exclusivity history# Additional Listing Data#
Finished product Yes
Brand name base Combogesic
Listing expiration 2026-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength ACETAMINOPHEN 325 mg/1 IBUPROFEN 97.5 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 2 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 362O9ITL9D Internal UNII lookup WK2XYI10QM Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 2 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 2675760 Internal RxNorm lookup 2675765 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 68788-4009-1 Combogesic 120 in 1 BOTTLE, PLASTIC TABLET, FILM COATED 120 1
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 4 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join Combogesic ACETAMINOPHEN AND IBUPROFEN Bryant Ranch Prepack a4f4ebdd-d4b0-49f4-9a3d-c2acfadc0161 2026-07-27 Boxed warning, Warnings, Adverse reactions Exact identifier application applno (NDA): 209471 application number: NDA209471 Combogesic ACETAMINOPHEN AND IBUPROFEN AFT Pharmaceuticals US, Inc. f863558f-2a44-41f8-a6b7-271851d4c2ff 2026-07-15 Boxed warning, Warnings, Adverse reactions Exact identifier application applno (NDA): 209471 application number: NDA209471 Combogesic ACETAMINOPHEN AND IBUPROFEN Preferred Pharmaceuticals Inc. cd03b658-dba1-4a12-8f6f-ab00da499c05 2025-09-04 Boxed warning, Warnings, Adverse reactions Exact identifier application applno (NDA): 209471 application number: NDA209471 ndc (product): 68788-4009 Combogesic ACETAMINOPHEN AND IBUPROFEN Hikma Pharmaceuticals USA Inc b32651c4-7fa0-415b-91eb-854aa1c28f2a 2025-01-14 Boxed warning, Warnings, Adverse reactions Exact identifier application applno (NDA): 209471 application number: NDA209471
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Marketing start Sample Exclude flag Status 68788-4009-1 68788400901 120 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (68788-4009-1) 2025-09-04 No No Current